Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells

Stem Cells

Volumn 26, Issue 3, 2008, Pages 789-797

  Eun, Su Jeon ^a   Hyun, Jung Moon ^a   Mi, Jeong Lee ^a   Hae, Young Song ^a   Young, Mi Kim ^a   Cho, Mong ^b   Suh, Dong Soo ^b   Yoon, Man Soo ^b   Chang, Chulhun L ^b   Jin, Sup Jung ^a   Jae, Ho Kim ^a,b  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Lysophosphatidic acid; Mesenchymal stem cells; Myofibroblasts; Stromal cell derived factor 1; smooth muscle actin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; LYSOPHOSPHOLIPID; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CELL DIFFERENTIATION; CELL TYPE; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MYOFIBROBLAST; MYOFIBROBLAST LIKE CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADIPOCYTE; ANIMAL; ASCITES; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; FIBROBLAST; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RAT; STEM CELL;

ACTINS; ADIPOCYTES; ADULT; AGED; ANIMALS; ASCITES; AUTOCRINE COMMUNICATION; CELL DIFFERENTIATION; CHEMOKINE CXCL12; FEMALE; FIBROBLASTS; HUMANS; LYSOPHOSPHOLIPIDS; MESENCHYMAL STEM CELLS; MIDDLE AGED; OVARIAN NEOPLASMS; RATS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SMAD2 PROTEIN; SMAD3 PROTEIN; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 43049148411     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2007-0742     Document Type: Article

References (55)

1. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-447.
2. Desmoulière A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-517.
3. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumorpromoting cell type. Cell Cycle 2006;5:1597-1601.
4. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 1990;63:21-29.
5. Tomasek JJ, Gabbiani G, Hinz B et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-363.
6. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
7. Sappino AP, Skalli O, Jackson B et al. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 1988;41:707-712.
8. Ganss R. Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cell Mol Med 2006;10:857-865.
9. Olumi AF, Grossfeld GD, Hayward SW et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-5011.
10. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-348.
11. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107:1761-1767.
12. Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004;15:477-489.
13. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-591.
14. Gaits F, Fourcade O, Le Balle F et al. Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett 1997;410:54-58.
15. Birgbauer E, Chun J. New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 2006;63:2695-2701.
16. Parizi M, Howard EW, Tomasek JJ. Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. Exp Cell Res 2000;254:210-220.
17. Tangkijvanich P, Melton AC, Chitapanarux T et al. Platelet-derived growth factor-BB and lysophosphatidic acid distinctly regulate hepatic myofibroblast migration through focal adhesion kinase. Exp Cell Res 2002;281:140-147.
18. Murph M, Tanaka T, Liu S et al. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 2006;12:6598-6602.
19. Xiao YJ, Schwartz B, Washington M et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 2001;290:302-313.
20. Xu Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-723.
21. Westermann AM, Havik E, Postma FR et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998;9:437-442.
22. Bian D, Su S, Mahanivong C et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 2004;64:4209-4217.
23. Xu Y, Fang XJ, Casey G et al. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995;309(Pt 3):933-940.
24. Boucharaba A, Serre CM, Guglielmi J et al. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006;103:9643-9648.
25. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568-584.
26. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74.
27. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
28. Short B, Brouard N, Occhiodoro-Scott T et al. Mesenchymal stem cells. Arch Med Res 2003;34:565-571.
29. Zhu W, Xu W, Jiang R et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006;80:267-274.
30. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007;127:526-537.
31. Li H, Fan X, Houghton J. Tumor microenvironment: The role of the tumor stroma in cancer. J Cell Biochem 2007;101:805-815.
32. Kinner B, Zaleskas JM, Spector M. Regulation of smooth muscle actin expression and contraction in adult human mesenchymal stem cells. Exp Cell Res 2002;278:72-83.
33. Wang D, Park JS, Chu JS et al. Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J Biol Chem 2004;279:43725-43734.
34. Jeon ES, Moon HJ, Lee MJ et al. Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-likecells through a TGF-beta-dependent mechanism. J Cell Sci 2006;119:4994-5005.
35. Fujii M, Takeda K, Imamura T et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999;10:3801-3813.
36. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-503.
37. Jeon ES, Song HY, Kim MR et al. Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK. J Lipid Res 2006;47:653-664.
38. Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol 2003;29:397-404.
39. Qiu P, Ritchie RP, Fu Z et al. Myocardin enhances Smad3-mediated transforming growth factor-beta1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22alpha transcription in vivo. Circ Res 2005;97:983-991.
40. Sinha S, Hoofnagle MH, Kingston PA et al. Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 2004;287:C1560-C1568.
41. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006;69:597-607.
42. Luquain C, Singh A, Wang L et al. Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. J Lipid Res 2003;44:1963-1975.
43. Eder AM, Sasagawa T, Mao M et al. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000;6:2482-2491.
44. Shen Z, Belinson J, Morton RE et al. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol 1998;71:364-368.
45. Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
46. Morishita R, Nagata K, Ito H et al. Expression of smooth muscle cell-specific proteins in neural progenitor cells induced by agonists of G protein-coupled receptors and transforming growth factor-beta. J Neurochem 2007;101:1031-1040.
47. Hayashi K, Takahashi M, Nishida W et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res 2001;89:251-258.
48. Gan Q, Yoshida T, Li J et al. Smooth muscle cells and myofibroblasts use Distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res 2007;101:883-892.
49. Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev 2006;17:29-40.
50. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-457.
51. Xu Y, Gaudette DC, Boynton JD et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995;1:1223-1232.
52. Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 2003;17:1570-1572.
53. Yamada T, Sato K, Komachi M et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004;279:6595-6605.
54. Ao M, Franco OE, Park D et al. Cross-talk between Paracrine-Acting Cytokine and Chemokine Pathways Promotes Malignancy in Benign Human Prostatic Epithelium. Cancer Res 2007;67:4244-4253.
55. Menon LG, Picinich S, Koneru R et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. STEM CELLS 2007;25:520-528.